权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Hepatitis B Clinical Research Network Clinical Center: Michigan - Hawaii Consortium

乙型肝炎临床研究网络临床中心：密歇根-夏威夷联盟

基本信息

批准号：
10057559
负责人：
ANNA S.F. LOK
金额：
$ 4.72万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
起止时间：
2008-09-30 至 2022-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10057559
关键词：
18 year old Acute Hepatitis Address Adult Ancillary Study Antibodies Antiviral Therapy Asians Behavior Canada Censuses Child Childhood Chronic Chronic Hepatitis B Clinical Clinical Immunology Clinical Research Clinical Trials Clinical Trials Network Clinical Virology Cohort Studies Collaborations Collection Combined Modality Therapy Conduct Clinical Trials Consensus Country Data Data Analyses Data Coordinating Center Development Disease Enrollment Epidemiologic Factors Epidemiology Epitopes Flare Funding Genomics Goals HBV Genotype HIV Hawaii Health Hepatic Hepatitis Hepatitis B Hepatitis B Prevalence Hepatitis B Surface Antigens Hepatitis B Therapy Hepatitis B Vaccines Hepatitis B Virus Hepatitis B e Antigens Hepatitis D High Prevalence Home environment Immigrant Immune Immune Tolerance Immunologics Immunology Imprisonment Incidence Infection Interferons Leadership Life Style Liver diseases Manuscripts Medical center Michigan National Health and Nutrition Examination Survey Natural History North America Outcome Pacific Island Americans Participant Pathogenesis Patient Representative Patients Pattern Pegylated Interferon Alfa Persons Phase Phenotype Play Policies Pregnancy Prevalence Primary carcinoma of the liver cells Protocols documentation Public Health Quality of life Research Research Personnel Research Priority Safety Sampling Serotyping Site Surface Tenofovir Therapeutic immunosuppression United States United States National Institutes of Health Universal Precautions Universities Variant Virus Diseases Virus Replication Withdrawal base clinical center clinically relevant clinically significant co-infection cohort data dissemination design entecavir high risk population improved industry partner liver transplantation peginterferon alfa-2a pilot trial public health relevance randomized trial repository response seroconversion symposium treatment response trial comparing virology

项目摘要

DESCRIPTION (provided by applicant): Hepatitis B virus (HBV) infection remains a major public health problem in the United States (US) with an estimate of up to 2.2 million persons chronically infected. The Hepatitis B Research Network (HBRN) was established in 2008 to address the research priorities identified at the 2008 NIH Consensus Conference on Hepatitis B. The HBRN comprises 13 clinical consortia (21 adult and 7 pediatric clinical centers) in the US and in Toronto, Canada, a data coordinating center, and an immunology center. During the initial funding cycle of HBRN, the investigators developed and implemented an observational cohort study, a clinical trial for patients in the immune tolerant phase and a clinical trial for patients in the immune active phase of HBV infection. This Clinical Center application comprises 2 sites: University of Michigan in Ann Arbor (PI: Dr. Lok) and University of Hawaii/Queen's Medical Center in Honolulu (PI: Dr. Tsai). The Michigan-Hawaii (MI-HI) team has made important contributions to the HBRN studies through enrollment and retention of patients, and data and biospecimen collection. Furthermore, we have played a key role in designing the study protocols and data forms, serving and chairing on HBRN committees, and drafting and editing abstracts and manuscripts. As Chair of the HBRN Steering Committee and Executive Committee since its inception, Dr. Lok has provided leadership in the design and execution of scientific studies, establishing policies for HBRN, and setting up collaboration with industry partners. The specific aims of the MI-HI consortium in the next funding cycle of HBRN are: 1) to continue to enroll patients into HBRN studies and to follow those who have been enrolled to study completion; 2) to contribute to the development of new study proposals making use of data and biospecimens that are collected to further our understanding of the epidemiology, natural history, pathogenesis, and treatment of hepatitis B; and 3) to participate in data analyses and dissemination through abstract presentations and manuscripts. The ancillary study we propose aims to determine: 1) prevalence of co-existent HBsAg and anti- HBs; 2) associating epidemiologic factors; 3) clinical significance; 4) quantitative HBsAg levels and correlation with anti-HBs levels; 5) prevalence of immune escape variants and mixed HBV genotypes/serotypes; and 6) epitope recognition and neutralizing ability of circulating anti-HBs in HBRN participants (adults and children) with co-existent HBsAg and anti-HBs.

项目成果

期刊论文数量（13）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Incidence and prediction of HBsAg seroclearance in a prospective multi-ethnic HBeAg-negative chronic hepatitis B cohort.

DOI：
10.1002/hep.32231
发表时间：
2022-03
期刊：
Hepatology (Baltimore, Md.)
影响因子：
0
作者：
Terrault NA;Wahed AS;Feld JJ;Cooper SL;Ghany MG;Lisker-Melman M;Perrillo R;Sterling RK;Khalili M;Chung RT;Rosenthal P;Fontana RJ;Sarowar A;Lau DTY;Wang J;Lok AS;Janssen HLA
通讯作者：
Janssen HLA

Does suppression of HBV replication by antiviral therapy confer the same benefit as host immune control of HBV?

通过抗病毒治疗抑制 HBV 复制是否与 HBV 宿主免疫控制具有相同的益处？